Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than 5 Million Units Expected Over Initial 5-Year Term

Innova is backed by leading investors and healthcare groups: Alkhabeer Capital, with more than $2.5 billion AUM; Tamer Group, a pharma manufacturing partner to Astellas and Daiichi Sankyo; and Cigalah Group, whose healthcare arm reports sales exceeding $2 billion * Initial purchase order of 126,000 Sky Premium Life units secured on execution of the agreement * Exclusive rights across Saudi Arabia for an initial five years, spanning pharmacies, retail and online platforms, with potential to renew for a further five * Orders of more than 5 million units expected over the initial five-year term * Access to one of the Kingdom's largest pharmacy networks — more than 250 pharmacies * Entry into a $3.26 billion Saudi nutraceuticals market, forecast to reach $5.96 billion by 2033 CHICAGO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM) (link), a diversified, vertically integrated global healthcare group, today announced an exclusive distribution agreement with Innova Healthcare (“Innova”), one of Saudi Arabia's largest retail pharmacy networks, covering the Company's proprietary Sky Premium Life range of food supplements across the Kingdom of Saudi Arabia. The agreement includes an initial purchase order of 126,000 units.